Eli Lilly and Co expects the U.S. Medicare health plan to back down from strict coverage limits on new Alzheimer s drugs as more evidence emerges in coming weeks showing that clearing amyloid. | April 21, 2023
Eli Lilly and Co expects the U.S. Medicare health plan to back down from strict coverage limits on new Alzheimer's drugs as more evidence emerges in coming weeks showing that clearing amyloid brain plaques can help patients, a company executive told Reuters.
Eli Lilly and Co expects the U.S. Medicare health plan to back down from strict coverage limits on new Alzheimer s drugs as more evidence emerges in coming weeks showing that clearing amyloid brain
By Deena Beasley and Julie Steenhuysen (Reuters) - Eli Lilly and Co expects the U.S. Medicare health plan to back down from strict coverage limits on .
(Reuters) - Eli Lilly and Co expects the U.S. Medicare health plan to back down from strict coverage limits on new Alzheimer's drugs as more evidence emerges in coming weeks showing that clearing amyloid brain plaques can help patients, a company executive told Reuters. | Apr. 21